{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-022575","form_type":"8-K","ticker":"BCTX","cik":"0001610820","company_name":"BriaCell Therapeutics Corp.","filed_at":"2023-06-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.660373+00:00","generated_at":"2026-06-13T16:20:08.159799+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"FDA approves BriaCell's registrational study design for Bria-IMT combo in advanced breast cancer","bullets":["FDA approved primary and secondary endpoints, study design, and patient population for Bria-IMT plus checkpoint inhibitor in advanced metastatic breast cancer.","Trial is randomized, open-label with three arms: Bria-IMT combo, physician's choice, and Bria-IMT alone.","Patients must have exhausted all other treatment options; recruitment and dosing begin summer 2023.","Upon statistically significant milestones, BriaCell may apply for full approval via BLA filing.","CEO notes FDA's route to accelerate development for difficult-to-treat patient population."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-022575","json":"https://secwatch.observer/filing/0001493152-23-022575.json","markdown":"https://secwatch.observer/filing/0001493152-23-022575.md","text":"https://secwatch.observer/filing/0001493152-23-022575.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1610820/000149315223022575/0001493152-23-022575-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1610820/000149315223022575/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T16:20:08.159799+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}